{"ticker": {"uuid": "99935b0b-e3ee-4231-a141-77be07c33b8b", "symbol": "MIST", "name": "Milestone Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Price to book forward of Milestone Pharmaceuticals Inc. \u2013 NASDAQ:MIST", "summary": "This article provides financial information for Milestone Pharmaceuticals Inc. (NASDAQ: MIST), specifically focusing on its price-to-book forward ratio. It notes that the market is currently closed, and no trades have occurred. The content appears to be a basic financial data dis", "url": "https://www.tradingview.com/symbols/NASDAQ-MIST/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T20:11:34", "published_display": "14 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Milestone Pharmaceuticals Inc (MIST) Institutional Confidence", "summary": "Milestone Pharmaceuticals Inc (MIST) has an institutional shareholding score of 3.00, placing it 192nd in the Biotechnology & Medical Research industry. The institutional shareholding proportion decreased by 48.38% quarter-over-quarter to 25.86%. Steven Cohen is the largest insti", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mist/sentiment", "source_name": "TradingKey", "published_at": "2026-07-10T08:10:11", "published_display": "10 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Milestone Pharmaceuticals Inc. announced the grant of 288,000 stock options to six new employees under its 2021 Inducement Plan. These options, granted on July 1, 2026, have an exercise price of $1.32 per share, and will vest over four years, with 25% vesting after one year and t", "url": "https://www.manilatimes.net/2026/07/03/tmt-newswire/globenewswire/milestone-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2377888", "source_name": "The Manila Times", "published_at": "2026-07-03T05:10:35", "published_display": "03 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone lures six new employees with 288,000 options", "summary": "Milestone Pharmaceuticals (Nasdaq:MIST) has granted a total of 288,000 stock options to six new employees as a material inducement for their hiring, in accordance with Nasdaq Listing Rule 5635(c)(4). The options, granted on July 1, 2026, have an exercise price of $1.32 per share,", "url": "https://www.stocktitan.net/news/MIST/milestone-pharmaceuticals-reports-inducement-grants-under-nasdaq-j993b41uieos.html", "source_name": "Stock Titan", "published_at": "2026-07-03T02:09:27", "published_display": "03 Jul 2026 02:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Milestone Pharmaceuticals Inc. \u2013 NASDAQ:MIST", "summary": "This article provides financial information for Milestone Pharmaceuticals Inc. (NASDAQ: MIST), specifically focusing on its enterprise value to EBIT forward. It is presented in the context of TradingView's platform, offering various financial tools and market data services.", "url": "https://www.tradingview.com/symbols/NASDAQ-MIST/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T17:43:25", "published_display": "01 Jul 2026 17:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Milestone Pharmaceuticals Inc. \u2013 NASDAQ:MIST", "summary": "The article provides the \"Price to sales forward\" value for Milestone Pharmaceuticals Inc. (NASDAQ: MIST). It lists the period, value, change, and percentage change for this financial metric. The content focuses solely on these financial details for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-MIST/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T03:39:37", "published_display": "01 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Milestone Pharmaceuticals Inc. \u2013 BOATS:MIST", "summary": "This article provides financial information for Milestone Pharmaceuticals Inc. (MIST) on the Blue Ocean Alternative Trade System (BOATS). It specifically highlights the company's enterprise value to EBIT forward, with a data table showing the period, value, and change.", "url": "https://www.tradingview.com/symbols/BOATS-MIST/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T01:10:04", "published_display": "01 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Milestone Pharmaceuticals Inc. \u2013 BOATS:MIST", "summary": "This article focuses on the enterprise value to revenue forward metric for Milestone Pharmaceuticals Inc. (MIST) as presented on the Blue Ocean Alternative Trade System (BOATS) within TradingView. It provides a snapshot of MIST's financial data with a focus on this specific valua", "url": "https://www.tradingview.com/symbols/BOATS-MIST/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T07:09:11", "published_display": "30 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MIST)", "summary": "This article provides an overview of Milestone Pharmaceuticals Inc. (NASDAQ: MIST) financial data and analyst estimates. It covers the stock's current price, performance over various periods, analyst forecasts, historical highs and lows, market capitalization, and upcoming earnin", "url": "https://www.tradingview.com/symbols/NASDAQ-MIST/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:09:34", "published_display": "26 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIST Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "Milestone Pharmaceuticals Inc. (MIST) has a current stock price of 1.25 USD. Analysts have provided price forecasts for MIST, with a max estimate of 8.00 USD and a min estimate of 2.00 USD. The company's financials include a market capitalization of 155.62M USD and upcoming earni", "url": "https://www.tradingview.com/symbols/NASDAQ-MIST/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T19:41:24", "published_display": "25 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Inc (MIST) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides details on the dividend and stock split history for Milestone Pharmaceuticals Inc (MIST) as of June 2026. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock splits. The stock was trading at $1.3", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mist/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T22:39:45", "published_display": "17 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Inc (MIST) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Milestone Pharmaceuticals Inc (MIST) has an earnings forecast score of 8.00 and an average price target of $4.00 from six analysts, with a \"Buy\" trend. The company's expected revenue for the next quarter is $1.10 million, and its EPS for the previous quarter was -$0.16, with an e", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mist/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T11:12:26", "published_display": "17 Jun 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals (MIST) investors approve equity plan, elect board and ratify PwC", "summary": "Milestone Pharmaceuticals shareholders approved an amendment to its 2019 Equity Incentive Plan, increasing authorized ordinary shares by 6,800,000 for future equity-based compensation. They also elected all eight director nominees, ratified PricewaterhouseCoopers LLP as the compa", "url": "https://www.stocktitan.net/sec-filings/MIST/8-k-milestone-pharmaceuticals-inc-reports-material-event-0707125a3515.html", "source_name": "Stock Titan", "published_at": "2026-06-15T20:06:13", "published_display": "15 Jun 2026 20:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone (NASDAQ: MIST) director receives 77,000 stock options grant", "summary": "Milestone Pharmaceuticals Inc. director Lisa M. Giles was granted 77,000 stock options with an exercise price of $1.22 per share, expiring on June 10, 2036. The options will vest in twelve equal monthly installments starting July 10, 2026, or fully by the next annual stockholder ", "url": "https://www.stocktitan.net/sec-filings/MIST/form-4-milestone-pharmaceuticals-inc-insider-trading-activity-20492de42fa0.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:38:43", "published_display": "12 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals (MIST) awards director 77,000 stock options", "summary": "Milestone Pharmaceuticals Inc. (MIST) director Duty Stuart was granted 77,000 stock options with an exercise price of $1.22 per share, expiring on June 10, 2036. The options will vest in twelve equal monthly installments starting July 10, 2026, and will be fully vested by the nex", "url": "https://www.stocktitan.net/sec-filings/MIST/form-4-milestone-pharmaceuticals-inc-insider-trading-activity-506b5e189504.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:38:43", "published_display": "12 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Milestone Pharmaceuticals (MIST) receives 77,000 stock options at $1.22", "summary": "Milestone Pharmaceuticals director Michael John Tomsicek was granted 77,000 stock options at an exercise price of $1.22 per share. These options will vest in twelve equal monthly installments starting July 10, 2026, and will be fully vested by the next annual stockholders\u2019 meetin", "url": "https://www.stocktitan.net/sec-filings/MIST/form-4-milestone-pharmaceuticals-inc-insider-trading-activity-96582ea5270e.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:38:43", "published_display": "12 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals (MIST) director receives 77,000 stock options at $1.22 strike", "summary": "Milestone Pharmaceuticals director Seth H. Z. Fischer was granted 77,000 stock options with a strike price of $1.22 per share, expiring on June 10, 2036. The options will vest in twelve equal monthly installments starting July 10, 2026, or fully vest at the next annual shareholde", "url": "https://www.stocktitan.net/sec-filings/MIST/form-4-milestone-pharmaceuticals-inc-insider-trading-activity-f8aeb7cd1e72.html", "source_name": "Stock Titan", "published_at": "2026-06-12T19:39:35", "published_display": "12 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals (MIST) director receives 77,000 stock options at $1.22", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNRkJCQ1JxNWVNOEt4T1FYcEs5M212ZF9vYXh3eEdsVjhhc1lXU3k3X3FSZ2RMSWlpWk51dXE4Sm84R202a2oycVlJTU5VeWE1a3owZDg5ZHU5cWJ4OHFkUklFQ00wQ2preFZtTUZPcUF0dHZVTVhFN3FXRFBmbl9DOEhWMDJJZlhkLVEzNzhSUmhERW9NMjJTSTBUb05Vc2UtOVVJTk5ERTBVcWkyVjNyTXVib0NDR19QcTljVzYwWFU?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals (MIST) director receives grant of 77,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQTmZHNTd3S1JuNGNiMEFDV3k4YmpYcks1dlF2MUlISWJQd1Uxdnc1QUJNQkFPVzVvSzAzQnJEZDhHWXcwdGUydHhrRjdjUmNzR01DZUtza1ZmbXNFTXJnM1ZaM0pTeVROMWcxMW1fc0ZLOGJsM2MyeHVkNHRZWjh5R0pUb3hnSUNHUUlXc2xYbjRJQW43Q0trVGkwcEdQNUhUcTA4aVExUVM2SkVpNFBhb19KUE1XZHpVN3Y5VG9rU1Q?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals: Here Comes The Revenue Ramp (NASDAQ:MIST)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOSERXTXBoSWNMclN4dWN6MzduMlkwRDRfT1Vmbm53bkFuMWFUX1lwODM4MFQ3a0NTNHdNSUFxMUkzNkNaTXF5QmI2XzFfdFk2MHh6UjRrbDdXN0ZxY3R0QldWWnZibHdxZ2d4emFEeGNvMkV3V00yaE1SVUNQdklQdnVXTWRYMGZvVzI4SHhiYW5HdnJrZmdFVUFR?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIST - Milestone Pharmaceuticals Inc Stock Price and Quote", "summary": "This article provides a comprehensive overview of Milestone Pharmaceuticals Inc. (MIST), including its stock price, key financial metrics, performance indicators, and recent news and analyst ratings. It details the company's focus on developing cardiovascular medicines, particula", "url": "https://finviz.com/stock?t=MIST", "source_name": "Finviz", "published_at": "2026-06-04T04:39:10", "published_display": "04 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals: Taking The Long View (NASDAQ:MIST)", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOaVJqYndLTTdHR3BOMnBBSldmd2dVWFhWOUNZQlJZNndzNmlpeFFkcktSMmNaUk1CMUJsWXM1ZmlsWVgtZkNqN3hnczJ0RVBaRjRNaGxnVnRFVVNzSE5MOTZPUENOLXRta1pUUU1LcWl1LUx5Z1RFOWE5cXdJeFhmWF9HVnk2aTdfLU43cmJHc0oxdTQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heart Rhythm Society and Milestone Pharmaceuticals Partner to Expand SVT Patient Education Through UpBeat.org", "summary": "The Heart Rhythm Society (HRS) and Milestone Pharmaceuticals have partnered to expand patient education for supraventricular tachycardia (SVT) through the UpBeat.org platform. This initiative, launched in recognition of SVT Awareness Day, provides new resources like info sheets, ", "url": "https://www.prnewswire.com/news-releases/heart-rhythm-society-and-milestone-pharmaceuticals-partner-to-expand-svt-patient-education-through-upbeatorg-302787608.html", "source_name": "PR Newswire", "published_at": "2026-06-01T21:40:21", "published_display": "01 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone (MIST) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/97425794-c73c-3f3e-b4ab-4ce8c49e7d10/milestone-%28mist%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-06-01T14:31:23+00:00", "published_display": "01 Jun 2026 14:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Milestone Pharmaceuticals Inc. SEC Filing", "summary": "This article reports on a Milestone Pharmaceuticals Inc. (MIST) SEC Filing, Form EFFECT, which became effective on May 22, 2026, at 4:00 P.M. The filing is a Notice of Effectiveness for an S-3 Shelf Registration Statement. The article also provides recent news and SEC filings rel", "url": "https://www.stocktitan.net/sec-filings/MIST/effect-milestone-pharmaceuticals-inc-sec-filing-dcaf31e6a6cc.html", "source_name": "Stock Titan", "published_at": "2026-05-26T10:38:42", "published_display": "26 May 2026 10:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paroxysmal Supraventricular Tachycardia Market Analysis Report 2026-2036, Profiles of Leading Players - Medtronic, Boston Scientific, Abbott Laboratories, Milestone Pharmaceuticals, Sanofi, Pfizer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/paroxysmal-supraventricular-tachycardia-market-analysis-130000387.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T13:00:00+00:00", "published_display": "21 May 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RTW Investments (MIST) and Roderick Wong disclose 9.99% ownership", "summary": "RTW Investments and Roderick Wong have disclosed a 9.99% beneficial ownership stake in Milestone Pharmaceuticals Inc. (MIST). This ownership includes 12,356,953 common shares, with the percentage calculated based on 117,667,277 shares outstanding as of March 20, 2026. The filing ", "url": "https://www.stocktitan.net/sec-filings/MIST/schedule-13g-a-milestone-pharmaceuticals-inc-amended-passive-investme-35c463b10b1d.html", "source_name": "Stock Titan", "published_at": "2026-05-15T12:10:26", "published_display": "15 May 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Inc. (NASDAQ:MIST): Is Breakeven Near?", "summary": "Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company, is projected to reach profitability by 2028, overcoming current losses of US$68 million. Analysts anticipate a final loss in 2027 before the company turns a profit of US$14 million in 2028, requiring an am", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mist/milestone-pharmaceuticals/news/milestone-pharmaceuticals-inc-nasdaqmist-is-breakeven-near", "source_name": "Simply Wall Street", "published_at": "2026-05-15T11:10:26", "published_display": "15 May 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Path To Profitability", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPVUhCNjNjSjlBVUtld0oyZjNBQUs1dEtTWTJ6ZjZVS3lPZEwwczZ0b0luTjFvSzI2NlR6Z21NejVMQmxsOFVtRTNoTFNTSWEyQjdkNU5YNnViQ3FaTU1rWmx5cGVVaEJFd1FyM1YzV2tNelpOOE51RG9qQXZ3S3UycEhaOE16VzNDQ1lsOThUVW5PRFJxWmU3V1hKYWJyZURCMUEzejNfazA3QQ?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/milestone-pharmaceuticals-present-h-c-123000789.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T12:30:00+00:00", "published_display": "14 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Q1 2026 Earnings Call Transcript", "summary": "Milestone Pharmaceuticals Inc. (NASDAQ:MIST) reported its Q1 2026 earnings, detailing the early commercial launch of CARDAMYST for acute PSVT episodes and the initiation of its Phase III trial for etripamil in AFib-RVR. The company notes positive initial responses from healthcare", "url": "https://www.insidermonkey.com/blog/milestone-pharmaceuticals-inc-nasdaqmist-q1-2026-earnings-call-transcript-1762080/", "source_name": "Insider Monkey", "published_at": "2026-05-14T12:39:25", "published_display": "14 May 2026 12:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NASDAQ fireside chat: Milestone talks cardiovascular drugs on May 19", "summary": "Milestone Pharmaceuticals (NASDAQ: MIST) announced it will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026, featuring a 3:00 p.m. ET fireside chat available via webcast. The company, focused on innovative cardiovascular medicines", "url": "https://www.stocktitan.net/news/MIST/milestone-pharmaceuticals-to-present-at-the-h-c-wainwright-4th-k832f6193bf0.html", "source_name": "Stock Titan", "published_at": "2026-05-14T12:39:25", "published_display": "14 May 2026 12:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone (Nasdaq: MIST) posts Q1 loss as first CARDAMYST sales begin", "summary": "Milestone Pharmaceuticals (Nasdaq: MIST) reported a widened net loss in Q1 2026, reaching $26.1 million, despite initiating its first product sales of CARDAMYST for paroxysmal supraventricular tachycardia (PSVT), generating $0.2 million in revenue. The company increased commercia", "url": "https://www.stocktitan.net/sec-filings/MIST/8-k-milestone-pharmaceuticals-inc-reports-material-event-1086e375cebb.html", "source_name": "Stock Titan", "published_at": "2026-05-14T09:10:41", "published_display": "14 May 2026 09:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Q1 Earnings Call Highlights", "summary": "Milestone Pharmaceuticals reported the start of commercial sales for its PSVT treatment, CARDEMYST, in Q1 2026, with approximately 600 prescriptions written by the end of April and steady month-over-month growth. The company also announced improved payer coverage with CARDEMYST a", "url": "https://www.marketbeat.com/instant-alerts/milestone-pharmaceuticals-q1-earnings-call-highlights-2026-05-13/", "source_name": "MarketBeat", "published_at": "2026-05-14T08:09:58", "published_display": "14 May 2026 08:09", "sentiment": "positive", "sentiment_pct": 81, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Milestone Pharmaceuticals Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/177aff8c-af65-3d7c-a1ff-ddb092ef8e0d/milestone-pharmaceuticals.html", "source_name": "Moby", "published_at": "2026-05-14T00:44:19+00:00", "published_display": "14 May 2026 00:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Inc (MIST) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/milestone-pharmaceuticals-inc-mist-q1-230056576.html", "source_name": "GuruFocus.com", "published_at": "2026-05-13T23:00:56+00:00", "published_display": "13 May 2026 23:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Files $300 Million Mixed Shelf", "summary": "Milestone Pharmaceuticals has filed a mixed shelf registration statement with the SEC, allowing it to offer and sell up to $300 million in various securities. This filing provides the company with financial flexibility for future capital-raising activities. The specific terms of ", "url": "https://www.moomoo.com/news/post/69952345/milestone-pharmaceuticals-files-300-million-mixed-shelf", "source_name": "Moomoo", "published_at": "2026-05-13T23:38:47", "published_display": "13 May 2026 23:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Inc. Stock 12\u2011Month Price Target Cut to $6.33, Implies 233% Upside", "summary": "Milestone Pharmaceuticals Inc.'s average 12-month price target has been reduced from $6.5 to $6.33 by six analysts, implying a 233% potential upside from its May 12 closing price. The consensus rating for MIST remains a \"Buy,\" with five analysts recommending Buy and one recommend", "url": "https://www.tradingview.com/news/tradingview:f311c9fb25acc:0-milestone-pharmaceuticals-inc-stock-12-month-price-target-cut-to-6-33-implies-233-upside/", "source_name": "TradingView", "published_at": "2026-05-13T22:38:47", "published_display": "13 May 2026 22:38", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Milestone Pharmaceuticals (MIST)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTFBmcFFCSHdlMXpMeVgwcFFNbHJ6TDJYQ1Z4VVc1Tkg4djI0UExuN3B2dFF0MlNacUhsRlRTZFR4Ri1UT2FCZVllbkdKbnR6SzNMdmxaSk1QUUpqWXBGZUNhRUFWOG5vN1VxLWVFdQ?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Milestone Pharmaceuticals Stock Wilted on Wednesday", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOekw4dnJNbTFlWS1KUWtLN0pLbXVORjNudzNvYlQ2TUsyelhKMnEwUTI1WmZUdEY1V3NjbXdpb1hBaEdMZTdWVVVhN0NHbHEzaklsTzlEdlNiZ2JCX3NfUjNMTU1SSFc0T2hPdjEyYlVVbmVpMkluS241b0xxV3BKenc4T2JUVjMtRDloX1FicjFZQVVUcnlqYg?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Releases Q1 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPeHVZZjlzMUxFakR5MV93MHdkcjlUcGNYRWJRa3BxZDQxUGlmT1I2UWlKN0hlenVJTWFyRFNjRWJCY2gxY3R0S3dsbzRaYlh4MWx6OVZqS2JTX1lROWVmNC11V3ctRFlkUHJuTVB1LTVUTnBZYklNNWJINnNLM2kwR1N3dFUwWHNSeWJBZE9RM0p2ZlVh0gGUAUFVX3lxTE94dVlmOXMxTEVqRHkxX3cwd2RyOVRwY1hFYlFrcHFkNDFQaWZPUjZRaUo3SGV6dUlNYXJEU2NFYkJjaDFjdHRLd2xvNFpiWHgxbHo5VmpLYlNfWVE5ZWY0LXVXdy1EWWRQcm5NUHUtNVROcFliSU01Ykg2c0szaTBHU3d0VTBYc1J5YkFkT1EzSnZmVWE?oc=5", "source_name": "AlphaStreet", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What date does Milestone Pharmaceuticals's (MIST) report Earnings - Earnings Calendar & Announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMia0FVX3lxTE9pREt3eDdFRmltYnZ0Y0owVzdpRTQ3WkZGQndwUlU0NVNLOEczVzV2RmtTN19aM2t2clY1d0ZzMkhNZUdIeEpHMjdTRERuSUhZRzliNDNzRlk1anRreGswZXhtTi1iS0pqeUJj?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals shares plunge after CARDAMYST revenue misses expectations (MIST)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNZTYxb2RZUEJxS01UVk1nQl9uRmtIYTFmVk5PdUVyZGpvSHJzcUh4SVdkS3hkOVVYMXlKLXZYcWROZG5xWlpVYlY2ZDhlZHZFVUxJb2pDVVRuY2JSMVNoejZOdHVCb3I0QjNkNFQ4WmNSZ00wSmxyMm02ZWt6TDJYektTSmRDczJOOVV4LVd1Y29HeHlZbXdTdU04SQ?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 15, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST\u2122 (etripamil) Nasal Spray for the Treatment of PSVT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPakhEM1duWnJIZ3E2SzdoUUxyem1oaXNqc3pHZ25kWV92OUVNMFFNZGtPZVJsblV5ZEhmdWJ1S1lYdjJaUFZQcWRjUXBHOVExVFhlamsyZS0yd20zQUNKbVdQM2dlbkZvUDhVS01zOVRNb19oMjU3QjlQTC0zd0NhX0x2VWx3aDFIODVZeDB0eEdDUGY0LURKVmwtMkE2VElhb1lQaFVOZFVjYUc0UklqZFRLdm1vaV8z?oc=5", "source_name": "Market source", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals (MIST) Is Down 16.3% After First-in-Decades At-Home PSVT Drug Approval - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-17T08:00:00+00:00", "published_display": "17 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals stock rating upgraded by TD Cowen to Buy on FDA approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQUy0yMzNSZGd3RHA2eUdHa2tsRmhsbUpoRlU3Ym5BQTZFSWNIcm1DS19qVml5bGxRNzJvdmpORFNsSjBtY3doNU5DS3l4T3ZkVkRzU0hvZEZsQTNXejVXeFlvZEo5T0tsSFdZWkhYY25kRkQxZUs5d2k4VXdYT0VMc09YbldvZWxkcXhnMmhUakF1Ukgxc3hyRmhjUDM0WHdJWnp3Mi1oNUVyMW5zOFJFVkI2VDZwWUNOZm9CQVBqUkN0eGxhV1gwbUdabmJwLUR0OHBKZGYyN1ZjZw?oc=5", "source_name": "Investing.com", "published_at": "2025-12-15T08:00:00+00:00", "published_display": "15 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone (NASDAQ: MIST) gains FDA approval for self-use CARDAMYST PSVT spray", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPQ0JEM0o5WmF1WHVCdUs1bXYzRDJqMVdDUjh0S2tLcTlfS3FxSndHMG51MlVvRWs4LV9OR3g1YlBTc3phTExxTHRkbklYY3Z1LUFiaG1HWUlSX294Sk5iT1VKeG1taVZHSlc0Sm12T3RxbmRKUFdka3NFNklxS09CdXo5QzlsU2M5eFZZV1NyNEZ1ZVUyRVF5R0tWWklTYkFzT1c2ZXV6QVJZdzZ4VExoQ296cEd1eE9lTHpFSg?oc=5", "source_name": "Stock Titan", "published_at": "2025-12-12T08:00:00+00:00", "published_display": "12 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Could Be 44% Below Their Intrinsic Value Estimate", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNZWgtaGVWNE00MXNmdTNLVllMQllRZllyejJ6ajk0bnVmOERDbW0zTnFkczZpbG9qRkUyQ0UzNEdza0NIRnFGVTRJNFZQU2ZwTUlYcldvR1NvOUh2eHNnUDhGaXlPMGh2REd4VTVfNmZ2eVV5MDBaZmpuWkthQTdPYmlxX1JnXzBHSktTNGVNZDM?oc=5", "source_name": "Market source", "published_at": "2025-11-18T08:00:00+00:00", "published_display": "18 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxOYmVPWjFaV0dhb1ZCMzdHT0xvUV9qUHFjT204XzVZWi13enZuUDRhMElmQWNiQjN6YkE5a0pxeWFsek9kX0ttUmU3Y05YcnltUDhaN0JTX1Bsb0tOTVo2SDkyOHJzOGRfRHYydlJFVDhCc3VyS0Nwd0otOFV1dFExNXZ4QXZSMllrV0lnSnhEaUpPMkJjM0FhV3ZiQ3MyQzVYVEFyWDM5S1hSaWdKTzNhbnNtU3JhMWFkaTBGY3NSUnItTWI2eUxYdkJIUExib0pjQjdGSnlhNjlkYTFVaXNSMEwtTi1FNzNNR0xEY1BBOHJuem_SAfgBQVVfeXFMUHd4OXRoRG8yd2ZKNTROWmhScDNlUXp4QkJNam81dEQwRzlIa1NfS1VSaUItdXV0TnRHTGZXV3VpdmJ3VTRFS1psOVdwTjR1TGs0Y1FYa3dJWnBrSXV4M3FjRjQtR3RVQi1hRW9aM2JsUGswR1RpWmh0RHFiY2x2cHBmTWxlWE1ROFlFZV9pbV96TDJMRXlQdUx4Yjc3MmloN1hLSjE2SHEzVDIySmRyWnBKQ3o2bDlfZ09KRTRNS1JzSmNVVzB3WkZsZVJsVzlNbG9FdXFEd1VRVEcwM2ZQQlB6QTNPMFItWUYwaFFxb1FxZkZpVjZLc0I?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-15T08:00:00+00:00", "published_display": "15 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Retail investors who have a significant stake must be disappointed along with institutions after Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) market cap dropped by US$9.0m", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-15T07:00:00+00:00", "published_display": "15 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray \u2013 But Retail\u2019s Positive", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQc2VCOG9QWTNrRjg2R3lLWWF3VTZhd3QzSVZZNGxGbTRTazJvSjJ0R09FRFNfT2pySjFmd01wX2NXb2JrWmZoWGM0NnQ0TlBxZlhJNDI4bVNJbGFXNExGOEFzSlhwejRNeUdldmZRZHNVTkpISU9aVFJ5R3RZenJrMTVPcW1hNkRPLUlXQ01ONXdVS0h1YngycDBaNVR4d1Joc2F4WWpKOG9HLV9nYUVlOHVPS2k3bFZaMk5XVHoxblU1bWFrOHZpVmZrMnIwdjZPQ1JJ?oc=5", "source_name": "Stocktwits", "published_at": "2025-03-28T17:21:59+00:00", "published_display": "28 Mar 2025 17:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA declines to approve Milestone's heart rhythm nasal spray; shares halve", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxOT1dSOGE4NC1hdFRXNTJpR1N4VU8zdXp1NTd0S3lBTE9ZRWV1RFZUSERlNlVnN200VzMyUG5FMTF5dmM4TW9RSk5sUnp2Q2RnTmNxR2F0LThaM0lrZ1lDczhCbVVMdGxOX2hYNTBHa1ZWX2RjNDBkTFZPMV9CQTA0bjQtS2lNNnRRbm5Ua242bmpWT1c5RW5WT2hiV3NaaGNwQWNwTlJyY3BrOG9Eak5EVkZ0bTFhZGZpVF9XRldMaWVVSTdWYU9tOGRWT0F1NGNOM21kdA?oc=5", "source_name": "Reuters", "published_at": "2025-03-28T07:00:00+00:00", "published_display": "28 Mar 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Price to book forward of Milestone Pharmaceuticals Inc. \u2013 NASDAQ:MIST", "summary": "This article provides financial information for Milestone Pharmaceuticals Inc. (NASDAQ: MIST), specifically focusing on its price-to-book forward ratio. It notes that the market is currently closed, and no trades have occurred. The content appears to be a basic financial data dis", "url": "https://www.tradingview.com/symbols/NASDAQ-MIST/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T20:11:34", "published_display": "14 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Inc (MIST) Institutional Confidence", "summary": "Milestone Pharmaceuticals Inc (MIST) has an institutional shareholding score of 3.00, placing it 192nd in the Biotechnology & Medical Research industry. The institutional shareholding proportion decreased by 48.38% quarter-over-quarter to 25.86%. Steven Cohen is the largest insti", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mist/sentiment", "source_name": "TradingKey", "published_at": "2026-07-10T08:10:11", "published_display": "10 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Milestone Pharmaceuticals Inc. announced the grant of 288,000 stock options to six new employees under its 2021 Inducement Plan. These options, granted on July 1, 2026, have an exercise price of $1.32 per share, and will vest over four years, with 25% vesting after one year and t", "url": "https://www.manilatimes.net/2026/07/03/tmt-newswire/globenewswire/milestone-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2377888", "source_name": "The Manila Times", "published_at": "2026-07-03T05:10:35", "published_display": "03 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone lures six new employees with 288,000 options", "summary": "Milestone Pharmaceuticals (Nasdaq:MIST) has granted a total of 288,000 stock options to six new employees as a material inducement for their hiring, in accordance with Nasdaq Listing Rule 5635(c)(4). The options, granted on July 1, 2026, have an exercise price of $1.32 per share,", "url": "https://www.stocktitan.net/news/MIST/milestone-pharmaceuticals-reports-inducement-grants-under-nasdaq-j993b41uieos.html", "source_name": "Stock Titan", "published_at": "2026-07-03T02:09:27", "published_display": "03 Jul 2026 02:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Milestone Pharmaceuticals Inc. \u2013 NASDAQ:MIST", "summary": "This article provides financial information for Milestone Pharmaceuticals Inc. (NASDAQ: MIST), specifically focusing on its enterprise value to EBIT forward. It is presented in the context of TradingView's platform, offering various financial tools and market data services.", "url": "https://www.tradingview.com/symbols/NASDAQ-MIST/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T17:43:25", "published_display": "01 Jul 2026 17:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Milestone Pharmaceuticals Inc. \u2013 NASDAQ:MIST", "summary": "The article provides the \"Price to sales forward\" value for Milestone Pharmaceuticals Inc. (NASDAQ: MIST). It lists the period, value, change, and percentage change for this financial metric. The content focuses solely on these financial details for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-MIST/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T03:39:37", "published_display": "01 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Milestone Pharmaceuticals Inc. \u2013 BOATS:MIST", "summary": "This article provides financial information for Milestone Pharmaceuticals Inc. (MIST) on the Blue Ocean Alternative Trade System (BOATS). It specifically highlights the company's enterprise value to EBIT forward, with a data table showing the period, value, and change.", "url": "https://www.tradingview.com/symbols/BOATS-MIST/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T01:10:04", "published_display": "01 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Milestone Pharmaceuticals Inc. \u2013 BOATS:MIST", "summary": "This article focuses on the enterprise value to revenue forward metric for Milestone Pharmaceuticals Inc. (MIST) as presented on the Blue Ocean Alternative Trade System (BOATS) within TradingView. It provides a snapshot of MIST's financial data with a focus on this specific valua", "url": "https://www.tradingview.com/symbols/BOATS-MIST/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T07:09:11", "published_display": "30 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MIST)", "summary": "This article provides an overview of Milestone Pharmaceuticals Inc. (NASDAQ: MIST) financial data and analyst estimates. It covers the stock's current price, performance over various periods, analyst forecasts, historical highs and lows, market capitalization, and upcoming earnin", "url": "https://www.tradingview.com/symbols/NASDAQ-MIST/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:09:34", "published_display": "26 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIST Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "Milestone Pharmaceuticals Inc. (MIST) has a current stock price of 1.25 USD. Analysts have provided price forecasts for MIST, with a max estimate of 8.00 USD and a min estimate of 2.00 USD. The company's financials include a market capitalization of 155.62M USD and upcoming earni", "url": "https://www.tradingview.com/symbols/NASDAQ-MIST/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T19:41:24", "published_display": "25 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Inc (MIST) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides details on the dividend and stock split history for Milestone Pharmaceuticals Inc (MIST) as of June 2026. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock splits. The stock was trading at $1.3", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mist/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T22:39:45", "published_display": "17 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Inc (MIST) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Milestone Pharmaceuticals Inc (MIST) has an earnings forecast score of 8.00 and an average price target of $4.00 from six analysts, with a \"Buy\" trend. The company's expected revenue for the next quarter is $1.10 million, and its EPS for the previous quarter was -$0.16, with an e", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mist/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T11:12:26", "published_display": "17 Jun 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals (MIST) investors approve equity plan, elect board and ratify PwC", "summary": "Milestone Pharmaceuticals shareholders approved an amendment to its 2019 Equity Incentive Plan, increasing authorized ordinary shares by 6,800,000 for future equity-based compensation. They also elected all eight director nominees, ratified PricewaterhouseCoopers LLP as the compa", "url": "https://www.stocktitan.net/sec-filings/MIST/8-k-milestone-pharmaceuticals-inc-reports-material-event-0707125a3515.html", "source_name": "Stock Titan", "published_at": "2026-06-15T20:06:13", "published_display": "15 Jun 2026 20:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone (NASDAQ: MIST) director receives 77,000 stock options grant", "summary": "Milestone Pharmaceuticals Inc. director Lisa M. Giles was granted 77,000 stock options with an exercise price of $1.22 per share, expiring on June 10, 2036. The options will vest in twelve equal monthly installments starting July 10, 2026, or fully by the next annual stockholder ", "url": "https://www.stocktitan.net/sec-filings/MIST/form-4-milestone-pharmaceuticals-inc-insider-trading-activity-20492de42fa0.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:38:43", "published_display": "12 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals (MIST) awards director 77,000 stock options", "summary": "Milestone Pharmaceuticals Inc. (MIST) director Duty Stuart was granted 77,000 stock options with an exercise price of $1.22 per share, expiring on June 10, 2036. The options will vest in twelve equal monthly installments starting July 10, 2026, and will be fully vested by the nex", "url": "https://www.stocktitan.net/sec-filings/MIST/form-4-milestone-pharmaceuticals-inc-insider-trading-activity-506b5e189504.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:38:43", "published_display": "12 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Milestone Pharmaceuticals (MIST) receives 77,000 stock options at $1.22", "summary": "Milestone Pharmaceuticals director Michael John Tomsicek was granted 77,000 stock options at an exercise price of $1.22 per share. These options will vest in twelve equal monthly installments starting July 10, 2026, and will be fully vested by the next annual stockholders\u2019 meetin", "url": "https://www.stocktitan.net/sec-filings/MIST/form-4-milestone-pharmaceuticals-inc-insider-trading-activity-96582ea5270e.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:38:43", "published_display": "12 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals (MIST) director receives 77,000 stock options at $1.22 strike", "summary": "Milestone Pharmaceuticals director Seth H. Z. Fischer was granted 77,000 stock options with a strike price of $1.22 per share, expiring on June 10, 2036. The options will vest in twelve equal monthly installments starting July 10, 2026, or fully vest at the next annual shareholde", "url": "https://www.stocktitan.net/sec-filings/MIST/form-4-milestone-pharmaceuticals-inc-insider-trading-activity-f8aeb7cd1e72.html", "source_name": "Stock Titan", "published_at": "2026-06-12T19:39:35", "published_display": "12 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals (MIST) director receives 77,000 stock options at $1.22", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNRkJCQ1JxNWVNOEt4T1FYcEs5M212ZF9vYXh3eEdsVjhhc1lXU3k3X3FSZ2RMSWlpWk51dXE4Sm84R202a2oycVlJTU5VeWE1a3owZDg5ZHU5cWJ4OHFkUklFQ00wQ2preFZtTUZPcUF0dHZVTVhFN3FXRFBmbl9DOEhWMDJJZlhkLVEzNzhSUmhERW9NMjJTSTBUb05Vc2UtOVVJTk5ERTBVcWkyVjNyTXVib0NDR19QcTljVzYwWFU?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals (MIST) director receives grant of 77,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQTmZHNTd3S1JuNGNiMEFDV3k4YmpYcks1dlF2MUlISWJQd1Uxdnc1QUJNQkFPVzVvSzAzQnJEZDhHWXcwdGUydHhrRjdjUmNzR01DZUtza1ZmbXNFTXJnM1ZaM0pTeVROMWcxMW1fc0ZLOGJsM2MyeHVkNHRZWjh5R0pUb3hnSUNHUUlXc2xYbjRJQW43Q0trVGkwcEdQNUhUcTA4aVExUVM2SkVpNFBhb19KUE1XZHpVN3Y5VG9rU1Q?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals: Here Comes The Revenue Ramp (NASDAQ:MIST)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOSERXTXBoSWNMclN4dWN6MzduMlkwRDRfT1Vmbm53bkFuMWFUX1lwODM4MFQ3a0NTNHdNSUFxMUkzNkNaTXF5QmI2XzFfdFk2MHh6UjRrbDdXN0ZxY3R0QldWWnZibHdxZ2d4emFEeGNvMkV3V00yaE1SVUNQdklQdnVXTWRYMGZvVzI4SHhiYW5HdnJrZmdFVUFR?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIST - Milestone Pharmaceuticals Inc Stock Price and Quote", "summary": "This article provides a comprehensive overview of Milestone Pharmaceuticals Inc. (MIST), including its stock price, key financial metrics, performance indicators, and recent news and analyst ratings. It details the company's focus on developing cardiovascular medicines, particula", "url": "https://finviz.com/stock?t=MIST", "source_name": "Finviz", "published_at": "2026-06-04T04:39:10", "published_display": "04 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals: Taking The Long View (NASDAQ:MIST)", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOaVJqYndLTTdHR3BOMnBBSldmd2dVWFhWOUNZQlJZNndzNmlpeFFkcktSMmNaUk1CMUJsWXM1ZmlsWVgtZkNqN3hnczJ0RVBaRjRNaGxnVnRFVVNzSE5MOTZPUENOLXRta1pUUU1LcWl1LUx5Z1RFOWE5cXdJeFhmWF9HVnk2aTdfLU43cmJHc0oxdTQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heart Rhythm Society and Milestone Pharmaceuticals Partner to Expand SVT Patient Education Through UpBeat.org", "summary": "The Heart Rhythm Society (HRS) and Milestone Pharmaceuticals have partnered to expand patient education for supraventricular tachycardia (SVT) through the UpBeat.org platform. This initiative, launched in recognition of SVT Awareness Day, provides new resources like info sheets, ", "url": "https://www.prnewswire.com/news-releases/heart-rhythm-society-and-milestone-pharmaceuticals-partner-to-expand-svt-patient-education-through-upbeatorg-302787608.html", "source_name": "PR Newswire", "published_at": "2026-06-01T21:40:21", "published_display": "01 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone (MIST) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/97425794-c73c-3f3e-b4ab-4ce8c49e7d10/milestone-%28mist%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-06-01T14:31:23+00:00", "published_display": "01 Jun 2026 14:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Milestone Pharmaceuticals Inc. SEC Filing", "summary": "This article reports on a Milestone Pharmaceuticals Inc. (MIST) SEC Filing, Form EFFECT, which became effective on May 22, 2026, at 4:00 P.M. The filing is a Notice of Effectiveness for an S-3 Shelf Registration Statement. The article also provides recent news and SEC filings rel", "url": "https://www.stocktitan.net/sec-filings/MIST/effect-milestone-pharmaceuticals-inc-sec-filing-dcaf31e6a6cc.html", "source_name": "Stock Titan", "published_at": "2026-05-26T10:38:42", "published_display": "26 May 2026 10:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paroxysmal Supraventricular Tachycardia Market Analysis Report 2026-2036, Profiles of Leading Players - Medtronic, Boston Scientific, Abbott Laboratories, Milestone Pharmaceuticals, Sanofi, Pfizer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/paroxysmal-supraventricular-tachycardia-market-analysis-130000387.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T13:00:00+00:00", "published_display": "21 May 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RTW Investments (MIST) and Roderick Wong disclose 9.99% ownership", "summary": "RTW Investments and Roderick Wong have disclosed a 9.99% beneficial ownership stake in Milestone Pharmaceuticals Inc. (MIST). This ownership includes 12,356,953 common shares, with the percentage calculated based on 117,667,277 shares outstanding as of March 20, 2026. The filing ", "url": "https://www.stocktitan.net/sec-filings/MIST/schedule-13g-a-milestone-pharmaceuticals-inc-amended-passive-investme-35c463b10b1d.html", "source_name": "Stock Titan", "published_at": "2026-05-15T12:10:26", "published_display": "15 May 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Inc. (NASDAQ:MIST): Is Breakeven Near?", "summary": "Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company, is projected to reach profitability by 2028, overcoming current losses of US$68 million. Analysts anticipate a final loss in 2027 before the company turns a profit of US$14 million in 2028, requiring an am", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mist/milestone-pharmaceuticals/news/milestone-pharmaceuticals-inc-nasdaqmist-is-breakeven-near", "source_name": "Simply Wall Street", "published_at": "2026-05-15T11:10:26", "published_display": "15 May 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Path To Profitability", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPVUhCNjNjSjlBVUtld0oyZjNBQUs1dEtTWTJ6ZjZVS3lPZEwwczZ0b0luTjFvSzI2NlR6Z21NejVMQmxsOFVtRTNoTFNTSWEyQjdkNU5YNnViQ3FaTU1rWmx5cGVVaEJFd1FyM1YzV2tNelpOOE51RG9qQXZ3S3UycEhaOE16VzNDQ1lsOThUVW5PRFJxWmU3V1hKYWJyZURCMUEzejNfazA3QQ?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/milestone-pharmaceuticals-present-h-c-123000789.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T12:30:00+00:00", "published_display": "14 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Q1 2026 Earnings Call Transcript", "summary": "Milestone Pharmaceuticals Inc. (NASDAQ:MIST) reported its Q1 2026 earnings, detailing the early commercial launch of CARDAMYST for acute PSVT episodes and the initiation of its Phase III trial for etripamil in AFib-RVR. The company notes positive initial responses from healthcare", "url": "https://www.insidermonkey.com/blog/milestone-pharmaceuticals-inc-nasdaqmist-q1-2026-earnings-call-transcript-1762080/", "source_name": "Insider Monkey", "published_at": "2026-05-14T12:39:25", "published_display": "14 May 2026 12:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NASDAQ fireside chat: Milestone talks cardiovascular drugs on May 19", "summary": "Milestone Pharmaceuticals (NASDAQ: MIST) announced it will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026, featuring a 3:00 p.m. ET fireside chat available via webcast. The company, focused on innovative cardiovascular medicines", "url": "https://www.stocktitan.net/news/MIST/milestone-pharmaceuticals-to-present-at-the-h-c-wainwright-4th-k832f6193bf0.html", "source_name": "Stock Titan", "published_at": "2026-05-14T12:39:25", "published_display": "14 May 2026 12:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone (Nasdaq: MIST) posts Q1 loss as first CARDAMYST sales begin", "summary": "Milestone Pharmaceuticals (Nasdaq: MIST) reported a widened net loss in Q1 2026, reaching $26.1 million, despite initiating its first product sales of CARDAMYST for paroxysmal supraventricular tachycardia (PSVT), generating $0.2 million in revenue. The company increased commercia", "url": "https://www.stocktitan.net/sec-filings/MIST/8-k-milestone-pharmaceuticals-inc-reports-material-event-1086e375cebb.html", "source_name": "Stock Titan", "published_at": "2026-05-14T09:10:41", "published_display": "14 May 2026 09:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Q1 Earnings Call Highlights", "summary": "Milestone Pharmaceuticals reported the start of commercial sales for its PSVT treatment, CARDEMYST, in Q1 2026, with approximately 600 prescriptions written by the end of April and steady month-over-month growth. The company also announced improved payer coverage with CARDEMYST a", "url": "https://www.marketbeat.com/instant-alerts/milestone-pharmaceuticals-q1-earnings-call-highlights-2026-05-13/", "source_name": "MarketBeat", "published_at": "2026-05-14T08:09:58", "published_display": "14 May 2026 08:09", "sentiment": "positive", "sentiment_pct": 81, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/177aff8c-af65-3d7c-a1ff-ddb092ef8e0d/milestone-pharmaceuticals.html", "source_name": "Moby", "published_at": "2026-05-14T00:44:19+00:00", "published_display": "14 May 2026 00:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Inc (MIST) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/milestone-pharmaceuticals-inc-mist-q1-230056576.html", "source_name": "GuruFocus.com", "published_at": "2026-05-13T23:00:56+00:00", "published_display": "13 May 2026 23:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Files $300 Million Mixed Shelf", "summary": "Milestone Pharmaceuticals has filed a mixed shelf registration statement with the SEC, allowing it to offer and sell up to $300 million in various securities. This filing provides the company with financial flexibility for future capital-raising activities. The specific terms of ", "url": "https://www.moomoo.com/news/post/69952345/milestone-pharmaceuticals-files-300-million-mixed-shelf", "source_name": "Moomoo", "published_at": "2026-05-13T23:38:47", "published_display": "13 May 2026 23:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Inc. Stock 12\u2011Month Price Target Cut to $6.33, Implies 233% Upside", "summary": "Milestone Pharmaceuticals Inc.'s average 12-month price target has been reduced from $6.5 to $6.33 by six analysts, implying a 233% potential upside from its May 12 closing price. The consensus rating for MIST remains a \"Buy,\" with five analysts recommending Buy and one recommend", "url": "https://www.tradingview.com/news/tradingview:f311c9fb25acc:0-milestone-pharmaceuticals-inc-stock-12-month-price-target-cut-to-6-33-implies-233-upside/", "source_name": "TradingView", "published_at": "2026-05-13T22:38:47", "published_display": "13 May 2026 22:38", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Milestone Pharmaceuticals (MIST)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTFBmcFFCSHdlMXpMeVgwcFFNbHJ6TDJYQ1Z4VVc1Tkg4djI0UExuN3B2dFF0MlNacUhsRlRTZFR4Ri1UT2FCZVllbkdKbnR6SzNMdmxaSk1QUUpqWXBGZUNhRUFWOG5vN1VxLWVFdQ?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Milestone Pharmaceuticals Stock Wilted on Wednesday", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOekw4dnJNbTFlWS1KUWtLN0pLbXVORjNudzNvYlQ2TUsyelhKMnEwUTI1WmZUdEY1V3NjbXdpb1hBaEdMZTdWVVVhN0NHbHEzaklsTzlEdlNiZ2JCX3NfUjNMTU1SSFc0T2hPdjEyYlVVbmVpMkluS241b0xxV3BKenc4T2JUVjMtRDloX1FicjFZQVVUcnlqYg?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Releases Q1 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPeHVZZjlzMUxFakR5MV93MHdkcjlUcGNYRWJRa3BxZDQxUGlmT1I2UWlKN0hlenVJTWFyRFNjRWJCY2gxY3R0S3dsbzRaYlh4MWx6OVZqS2JTX1lROWVmNC11V3ctRFlkUHJuTVB1LTVUTnBZYklNNWJINnNLM2kwR1N3dFUwWHNSeWJBZE9RM0p2ZlVh0gGUAUFVX3lxTE94dVlmOXMxTEVqRHkxX3cwd2RyOVRwY1hFYlFrcHFkNDFQaWZPUjZRaUo3SGV6dUlNYXJEU2NFYkJjaDFjdHRLd2xvNFpiWHgxbHo5VmpLYlNfWVE5ZWY0LXVXdy1EWWRQcm5NUHUtNVROcFliSU01Ykg2c0szaTBHU3d0VTBYc1J5YkFkT1EzSnZmVWE?oc=5", "source_name": "AlphaStreet", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What date does Milestone Pharmaceuticals's (MIST) report Earnings - Earnings Calendar & Announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMia0FVX3lxTE9pREt3eDdFRmltYnZ0Y0owVzdpRTQ3WkZGQndwUlU0NVNLOEczVzV2RmtTN19aM2t2clY1d0ZzMkhNZUdIeEpHMjdTRERuSUhZRzliNDNzRlk1anRreGswZXhtTi1iS0pqeUJj?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals shares plunge after CARDAMYST revenue misses expectations (MIST)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNZTYxb2RZUEJxS01UVk1nQl9uRmtIYTFmVk5PdUVyZGpvSHJzcUh4SVdkS3hkOVVYMXlKLXZYcWROZG5xWlpVYlY2ZDhlZHZFVUxJb2pDVVRuY2JSMVNoejZOdHVCb3I0QjNkNFQ4WmNSZ00wSmxyMm02ZWt6TDJYektTSmRDczJOOVV4LVd1Y29HeHlZbXdTdU04SQ?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 15, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST\u2122 (etripamil) Nasal Spray for the Treatment of PSVT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPakhEM1duWnJIZ3E2SzdoUUxyem1oaXNqc3pHZ25kWV92OUVNMFFNZGtPZVJsblV5ZEhmdWJ1S1lYdjJaUFZQcWRjUXBHOVExVFhlamsyZS0yd20zQUNKbVdQM2dlbkZvUDhVS01zOVRNb19oMjU3QjlQTC0zd0NhX0x2VWx3aDFIODVZeDB0eEdDUGY0LURKVmwtMkE2VElhb1lQaFVOZFVjYUc0UklqZFRLdm1vaV8z?oc=5", "source_name": "Market source", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals (MIST) Is Down 16.3% After First-in-Decades At-Home PSVT Drug Approval - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-17T08:00:00+00:00", "published_display": "17 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals stock rating upgraded by TD Cowen to Buy on FDA approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQUy0yMzNSZGd3RHA2eUdHa2tsRmhsbUpoRlU3Ym5BQTZFSWNIcm1DS19qVml5bGxRNzJvdmpORFNsSjBtY3doNU5DS3l4T3ZkVkRzU0hvZEZsQTNXejVXeFlvZEo5T0tsSFdZWkhYY25kRkQxZUs5d2k4VXdYT0VMc09YbldvZWxkcXhnMmhUakF1Ukgxc3hyRmhjUDM0WHdJWnp3Mi1oNUVyMW5zOFJFVkI2VDZwWUNOZm9CQVBqUkN0eGxhV1gwbUdabmJwLUR0OHBKZGYyN1ZjZw?oc=5", "source_name": "Investing.com", "published_at": "2025-12-15T08:00:00+00:00", "published_display": "15 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone (NASDAQ: MIST) gains FDA approval for self-use CARDAMYST PSVT spray", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPQ0JEM0o5WmF1WHVCdUs1bXYzRDJqMVdDUjh0S2tLcTlfS3FxSndHMG51MlVvRWs4LV9OR3g1YlBTc3phTExxTHRkbklYY3Z1LUFiaG1HWUlSX294Sk5iT1VKeG1taVZHSlc0Sm12T3RxbmRKUFdka3NFNklxS09CdXo5QzlsU2M5eFZZV1NyNEZ1ZVUyRVF5R0tWWklTYkFzT1c2ZXV6QVJZdzZ4VExoQ296cEd1eE9lTHpFSg?oc=5", "source_name": "Stock Titan", "published_at": "2025-12-12T08:00:00+00:00", "published_display": "12 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Could Be 44% Below Their Intrinsic Value Estimate", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNZWgtaGVWNE00MXNmdTNLVllMQllRZllyejJ6ajk0bnVmOERDbW0zTnFkczZpbG9qRkUyQ0UzNEdza0NIRnFGVTRJNFZQU2ZwTUlYcldvR1NvOUh2eHNnUDhGaXlPMGh2REd4VTVfNmZ2eVV5MDBaZmpuWkthQTdPYmlxX1JnXzBHSktTNGVNZDM?oc=5", "source_name": "Market source", "published_at": "2025-11-18T08:00:00+00:00", "published_display": "18 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxOYmVPWjFaV0dhb1ZCMzdHT0xvUV9qUHFjT204XzVZWi13enZuUDRhMElmQWNiQjN6YkE5a0pxeWFsek9kX0ttUmU3Y05YcnltUDhaN0JTX1Bsb0tOTVo2SDkyOHJzOGRfRHYydlJFVDhCc3VyS0Nwd0otOFV1dFExNXZ4QXZSMllrV0lnSnhEaUpPMkJjM0FhV3ZiQ3MyQzVYVEFyWDM5S1hSaWdKTzNhbnNtU3JhMWFkaTBGY3NSUnItTWI2eUxYdkJIUExib0pjQjdGSnlhNjlkYTFVaXNSMEwtTi1FNzNNR0xEY1BBOHJuem_SAfgBQVVfeXFMUHd4OXRoRG8yd2ZKNTROWmhScDNlUXp4QkJNam81dEQwRzlIa1NfS1VSaUItdXV0TnRHTGZXV3VpdmJ3VTRFS1psOVdwTjR1TGs0Y1FYa3dJWnBrSXV4M3FjRjQtR3RVQi1hRW9aM2JsUGswR1RpWmh0RHFiY2x2cHBmTWxlWE1ROFlFZV9pbV96TDJMRXlQdUx4Yjc3MmloN1hLSjE2SHEzVDIySmRyWnBKQ3o2bDlfZ09KRTRNS1JzSmNVVzB3WkZsZVJsVzlNbG9FdXFEd1VRVEcwM2ZQQlB6QTNPMFItWUYwaFFxb1FxZkZpVjZLc0I?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-15T08:00:00+00:00", "published_display": "15 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Retail investors who have a significant stake must be disappointed along with institutions after Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) market cap dropped by US$9.0m", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-15T07:00:00+00:00", "published_display": "15 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray \u2013 But Retail\u2019s Positive", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQc2VCOG9QWTNrRjg2R3lLWWF3VTZhd3QzSVZZNGxGbTRTazJvSjJ0R09FRFNfT2pySjFmd01wX2NXb2JrWmZoWGM0NnQ0TlBxZlhJNDI4bVNJbGFXNExGOEFzSlhwejRNeUdldmZRZHNVTkpISU9aVFJ5R3RZenJrMTVPcW1hNkRPLUlXQ01ONXdVS0h1YngycDBaNVR4d1Joc2F4WWpKOG9HLV9nYUVlOHVPS2k3bFZaMk5XVHoxblU1bWFrOHZpVmZrMnIwdjZPQ1JJ?oc=5", "source_name": "Stocktwits", "published_at": "2025-03-28T17:21:59+00:00", "published_display": "28 Mar 2025 17:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA declines to approve Milestone's heart rhythm nasal spray; shares halve", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxOT1dSOGE4NC1hdFRXNTJpR1N4VU8zdXp1NTd0S3lBTE9ZRWV1RFZUSERlNlVnN200VzMyUG5FMTF5dmM4TW9RSk5sUnp2Q2RnTmNxR2F0LThaM0lrZ1lDczhCbVVMdGxOX2hYNTBHa1ZWX2RjNDBkTFZPMV9CQTA0bjQtS2lNNnRRbm5Ua242bmpWT1c5RW5WT2hiV3NaaGNwQWNwTlJyY3BrOG9Eak5EVkZ0bTFhZGZpVF9XRldMaWVVSTdWYU9tOGRWT0F1NGNOM21kdA?oc=5", "source_name": "Reuters", "published_at": "2025-03-28T07:00:00+00:00", "published_display": "28 Mar 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 99, "total_relevant": 60, "sentiment_summary": {"positive": 9, "negative": 5, "neutral": 46, "score": 52, "total": 60, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 16.45, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 11.7, "count": 22}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 9, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 1.28, "latest_week": "2026-07-10", "one_week_move": -3.0, "four_week_move": 0.8, "twelve_week_move": -39.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.460097, "market_dynamics_buy_signal": false, "relative_strength": -38.835214, "fair_value_gap": -31.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 49.4574, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.0% over one week, +0.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 59, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 13}, {"label": "TradingView", "count": 9}, {"label": "Market source", "count": 9}, {"label": "simplywall.st", "count": 5}, {"label": "TradingKey", "count": 3}, {"label": "Seeking Alpha", "count": 2}, {"label": "GlobeNewswire", "count": 2}, {"label": "Zacks Investment Research", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 22}, {"label": "Analyst action", "count": 4}, {"label": "Deals and strategy", "count": 2}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "5", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-3.0% over one week, +0.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Price to book forward of Milestone Pharmaceuticals Inc. \u2013 NASDAQ:MIST"}], "updated_at": "2026-07-16T15:23:05.750703+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}